$APYX

Apyx Medical Corporation reported its Q4 2025 earnings, revealing a significant increase in revenue compared to the previous year. The company highlighted advancements in its Apyx’s technology and a growing market demand for its products. Despite challenges in supply chain logistics, management remains optimistic about future growth and profitability. The commercial strategy appears to be yielding positive results with increased sales backlog and strong customer satisfaction. However, analysts raised concerns about potential regulatory hurdles that may impact growth projections.